PTSD trials with top 10 pharma company & US DoD

RNS Number : 9994T

Cambridge Cognition Holdings PLC

28 July 2022

 

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Cambridge Cognition wins PTSD trials with top 10 pharmaceutical company

and the United States Department of Defense

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce two agreements in a new therapeutic area for the Company, post-traumatic stress disorder ("PTSD").  Most recently, a research agreement was entered into with the with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.  Approximately 20 PTSD treatment trials run every year¹, demonstrating the potential for further sales in this therapeutic area.  

PTSD affects around 15 million adults a year² and up to 31% of veterans, many of whom do not experience relief from their symptoms with existing medications. It has been suggested that the symptoms of PTSD could directly lead to deficits in executive functioning,  including re-experiencing memories, problems with concentration, and hyperarousal interrupting working memory performance³. 

Only two pharmacological treatments for PTSD have received FDA-approval. One reason for this could be that drug response is highly variable between affected individuals, making it difficult to develop effective treatments. In efforts to address the therapeutic need, the United States Department of Defense is developing a precision medicine approach to PTSD. Cambridge Cognition has been selected as a cognitive assessment provider for the project because CANTAB^TM offers accurate measurement of the potentially distinct pathophysiological processes involved in PTSD.

Pharmaceutical companies are also investigating the potential for new drug classes for PTSD.  Recently, a top 10 pharmaceutical company has contracted with Cambridge Cognition to be their cognitive assessment partner for an upcoming PTSD treatment trial. In delivering the contract, Cambridge Cognition will provide its proprietary cognitive assessment tool, CANTAB^TM, as an exploratory endpoint.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Cognitive impairment is increasingly recognised as a major component of PTSD.  At Cambridge Cognition, we are pleased to be providing the company's expertise to monitor cognitive symptoms with a view to improving outcomes for those suffering from the after-effects of major trauma."

For further information, contact:

Cambridge Cognition Holdings Plc Matthew Stork, Chief Executive Officer Stephen Symonds, Chief Financial Officer	Tel: [phone] [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Joint Broker) Freddy Crossley / Emma Earl Rupert Dearden	Tel: [phone] (Corporate Finance) (Corporate Broking)
Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant	Tel: [phone]
IFC Advisory Ltd (Financial PR and IR) Tim Metcalfe / Graham Herring / Zach Cohen	Tel: [phone]

References

1.  TrialTrove search of PhI - IV PTSD Trials 2011 - 2021

2.  US Department of Veteran Affairs. https://www.ptsd.va.gov/understand/common/common_adults.asp

3.  Vasterling, J. J., Duke, L. M., Brailey, K., Constans, J. I., Allain, A. N., Jr., & Sutker, P. B. (2002). Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons. Neuropsychology, 16, 5-14.  

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

END

 

 

MSCDZGZNLNKGZZM